オプションチェーンは、Treace Medical Conceptsの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Treace Medical Conceptsの市場センチメントを評価します。.

Treace Medical Concepts (NASDAQ:TMCI) 株価情報, オプションチェーン

Treace Medical Concepts

Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The Company operates and manages its business as one segment, which is the business of designing, manufacturing, and marketing medical devices for physicians, surgeons, ambulatory surgery centers and hospitals.

Treace Medical Concepts, Inc. - Common Stock

Treace Medical Concepts Inc

WIIM

LYFT

UBER

Uber and Lyft shares are trading lower after Tesla CEO Elon Musk said Tesla has been testing self-driving Model Y cars on Austin public streets with no incidents.

Plug Power, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLUG#NASDAQ">PLUG</a>) shares are trading higher on Thursday after it announced record-breaking production figures <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/g45665465/plug-powers-georgia-hydrogen-plant-sets-u-s-production-record-using-plug-electrolyzer-technology" rel="noreferrer noopener">from its hydrogen facility in Georgia</a>.
The milestone adds momentum to Plug&#8217;s broader ambitions in the clean energy space as it continues expanding its hydrogen generation network.
The company revealed that its liquid hydrogen facility in Woodbine, Georgia produced 300 metric tons of liquid hydrogen in April 2025, marking its highest monthly output since operations began.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/25/05/45417895/jp-morgan-signals-caution-on-plug-powers-near-term-challenges-withdraws-price-forecast" rel="noreferrer noopener">JP Morgan Signals Caution On Plug Power&#8217;s Near-Term Challenges, Withdraws Price Forecast</a>
The site, which launched in January 2024, stands as the largest electrolytic liquid hydrogen plant in the United States and is a core element of Plug&#8217;s vertically integrated clean energy strategy.
Powered by Plug&#8217;s proprietary GenEco proton exchange membrane electrolyzer technology, the Georgia plant was built to deliver 15 tons per day at full capacity.
According to Andy Marsh, Plug&#8217;s CEO, &#8220;Plug&#8217;s Georgia plant is doing exactly what it was built to do, delivering real hydrogen at real scale using Plug technology.&#8221;
Marsh emphasized that the operation reflects Plug&#8217;s commitment to commercial hydrogen production, rather than just pilot programs or conceptual initiatives.
The Woodbine facility is one of several sites within Plug&#8217;s expanding U.S. hydrogen infrastructure, which includes plants in Tennessee and Louisiana.
Combined, these operations are capable of producing 40 tons of liquid hydrogen daily, securing Plug&#8217;s position as the nation&#8217;s largest liquid hydrogen producer.
Jose Luis Crespo, Plug&#8217;s Chief Revenue Officer, stated that strong output in Georgia validates customer demand for GenEco electrolyzers and strengthens long-term growth.
&#8220;Producing and delivering hydrogen with our own technology strengthens customer value, improves margins, and supports long-term commercial growth,&#8221; he said.
According to&nbsp;<a target="_blank" href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" rel="noreferrer noopener">Benzinga Pro</a>, PLUG stock has lost over 70% in the past year. Investors can gain exposure to the stock via&nbsp;Global X Hydrogen ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HYDR#NASDAQ">HYDR</a>).
Price Action: PLUG shares are trading higher by 2.45% to $0.9492&nbsp;at last check Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/government/regulations/25/05/45669445/us-economy-contracts-by-02-in-q1-labor-market-shows-signs-of-cracks-as-jobless-claims-surge" target="_blank" rel="noreferrer noopener">US Economy Contracts By 0.2% In Q1, Labor Market Shows Signs Of Cracks As Jobless Claims Surge</a></li>
</ul>
Photo via Shutterstock

Equities

News

Markets

Movers

General

HYDR

PLUG

Plug Power's Record Hydrogen Output In Georgia Signals Growth Potential

Shares of Reddit, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) are trading higher Thursday after the company was named among the additions to the Russell 3000 index<a href="https://www.benzinga.com/pressreleases/25/05/b45641852/reddit-set-to-join-russell-3000-index"> on Wednesday.</a>
What To Know: FTSE Russell confirmed on Wednesday that Reddit will join the Russell 3000 at the close of trading on June 27, 2025, as part of its annual index reconstitution. This inclusion means Reddit will also be added to either the Russell 1000 or Russell 2000 index, determined by objective, market-capitalization rankings and style attributes.
The addition is significant because Russell indexes are commonly used by institutional investors and index funds as benchmarks. As of June 2024, roughly $10.6 trillion in assets were benchmarked to these indexes. Companies added to the Russell 3000 often see increased investor attention and inflows due to automatic fund rebalancing.
Reddit went public in March 2024 and remains one of the most visited websites globally. 
The stock's movement reflects optimism surrounding its increased visibility and potential demand from index-tracking investors leading up to the June 27 effective date.
RDDT Price Action: Reddit shares were up 3.48% at $109.1 at the time of writing, according to <a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2">Benzinga pro.</a>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45677482/stocks-edge-higher-nvidia-rallies-to-3-month-highs-bitcoin-dips-below-107000-whats-driving-markets-thursday">Stocks Edge Higher After Court Stifles Trump Tariffs, Nvidia Rallies To 3-Month Highs, Bitcoin Dips Below $107K: What&#8217;s Driving Markets Thursday?</a></li>
</ul>
Image Via Shutterstock.

RDDT

What's Going On With Reddit Shares Today?

Mullen Automotive Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MULN#NASDAQ">MULN</a>) shares are diving Thursday after the company announced a <a href="https://www.benzinga.com/pressreleases/25/05/g45668272/mullen-automotive-inc-announces-reverse-stock-split-effective-june-2-2025">1-for-100 reverse stock split</a>. 
What To Know: Electric vehicle manufacturer Mullen announced that it will effect a 1-for-100 reverse stock split of its common stock, effective June 2. The company&#8217;s stock will begin trading on a split-adjusted basis at the market open on Monday.
Mullen said the reverse stock split is intended to bring the company into compliance with the Nasdaq&#8217;s minimum bid listing requirements of $1 per share. 
Mullen shareholders voted to approve a proposal on May 21 allowing the company to authorize a reverse stock split in the range of 1-for-2 to 1-for-250. The company&#8217;s board approved the 1-for-100 reverse split this week. 
No fractional shares will be issued in connection with the split. All fractional shares will be rounded up to the nearest whole share.
<h3 class="wp-block-heading">How to Buy MULN Stock</h3>
By now you're likely curious about how to participate in the market for Mullen Automotive &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.
In the case of Mullen Automotive, which is trading at $0.11 as of publishing time, $100 would buy you 909.09 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
MULN Price Action: <a href="http://benzinga.com/quote/muln" target="_blank" rel="noreferrer noopener">Mullen Automotive shares</a> were down 28.4% at $0.1089 at the time of publication Thursday, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>. Mullen shares are now down more than 99% year-to-date. The company has a market cap of just $6.76 million as of Wednesday&#8217;s close. 
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45677482/stocks-edge-higher-nvidia-rallies-to-3-month-highs-bitcoin-dips-below-107000-whats-driving-markets-thursday">Stocks Edge Higher After Court Stifles Trump Tariffs, Nvidia Rallies To 3-Month Highs, Bitcoin Dips Below $107K: What&#8217;s Driving Markets Thursday?</a></li>
</ul>
Photo: courtesy of Mullen Automotive.

Stock Split

MULN

Mullen Automotive Stock Is Tumbling Thursday: What's Driving The Action?

Despite delivering a staggering 1,100% return since October 2022, Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) may still have <a href="https://www.benzinga.com/topic/semiconductors">meaningful upside ahead</a>.
On Thursday, Bank of America's top semiconductor analyst Vivek Arya reiterated a Buy rating on the stock. He lifted his earnings forecasts and boosted the price target from $160 to $180. This implies a further 30% rally from current levels.
Shares climbed 3% to $139 by 2:00 p.m. ET, touching $143.84 intraday — the highest since February — as investor confidence grew on the heels of Nvidia's latest earnings report. The Santa Clara, California-based firm highlighted resilient margins and <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/05/45675006/nvidia-stock-has-significant-upside-as-ai-godfather-jensen-huang-delivers-another-robust-quarter">accelerating data center momentum.</a>
See Also: <a href="https://www.benzinga.com/25/05/45677482/stocks-edge-higher-nvidia-rallies-to-3-month-highs-bitcoin-dips-below-107000-whats-driving-markets-thursday">Stocks Edge Higher After Court Stifles Trump Tariffs, Nvidia Rallies To 3-Month Highs: What&#8217;s Driving Markets Thursday?</a>
<h3 class="wp-block-heading">Nvidia's Growth Story Just Got Even Stronger</h3>
Arya is forecasting long-term earnings power of $10 per share, driven by the company's AI hardware dominance.
Arya estimates Nvidia holds 80-85% of the total market for AI data center chips — a position he describes as &#8220;best-in-class in opportunity and execution.&#8221;
The expert upped the earnings forecast for calendar year 2027 to $7.23 per share, up 12%. One of the key reasons for this upgrade is the rapid ramp-up of Nvidia's Blackwell platform. 
"Blackwell racks are now in full production," Arya said, with major hyperscalers deploying close to 1,000 units per week. 
Given a $2.5 million-plus average selling price per rack, this points to a quarterly revenue opportunity exceeding $30 billion. When extended across Nvidia's top-tier customers, that could mean over $100 billion in annual revenue potential from just a few hyperscalers.
The analyst also noted that China is now "de-risked," as Nvidia's $15 billion in H20 chip sales for the first half of 2025 have already been modeled. That visibility into China demand reduces near-term geopolitical uncertainty, a major concern for investors following tightening U.S. export controls.
Another pivotal development is the expected rebound in gross margins, which Arya sees returning to the mid-70% range by the end of 2025. 
This improvement, he said, is a "sign of improving demand and rack-scale execution," helped in part by networking solutions like NVLink, Spectrum-X and BlueField, which are now widely deployed.
<h3 class="wp-block-heading">Cash Flow Strengthens The Investment Case</h3>
Arya continues to see Nvidia's fundamentals as uniquely strong. The company's free cash flow margin is hovering around 50%, more than twice the 19% average among the &#8216;Magnificent Seven.&#8217; 
He also underscored Nvidia's compelling valuation, with a price-to-earnings-to-growth ratio of just 0.9 compared to 3.0 for the peer group.
According to Arya, Nvidia stands to gain even more from the global AI infrastructure push, especially as capital expenditures extend beyond U.S. tech firms. 
"AI capex is diversifying from just U.S. clouds to now multiple sovereign deployments," Arya said, pointing to recent developments in Saudi Arabia.
Using a broader total addressable market estimate of $450 billion to $500 billion, Arya indicates Nvidia could hit or surpass $10 per share in earnings by 2027 if its current market share holds.
<h3 class="wp-block-heading">What Could Go Wrong?</h3>
Still, Arya acknowledged several execution risks. The company's plan to launch major new products on an annual cycle — each October — could strain its supply chain and internal operations. 
"Faster product cadence increases execution risks," he said, referencing delays seen during the initial Blackwell rollout.
He also flagged that reliable power and infrastructure remain key constraints in AI deployment. 
"Deployment of data centers with reliable access to high power is as much of a bottleneck as access to chips," Arya said.
Last but not least, with AI now a strategic asset in global politics, Nvidia remains vulnerable to regulatory and trade policy risks — especially involving China and export controls.
Now Read:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/media/25/05/45664231/teslas-optimus-may-be-the-first-humanoid-robot-to-achieve-high-volume-and-tech-scale-says-nvidia-ceo-jensen-huang-likely-to-be-the-next-multi-trillion-dollar-industry">Tesla&#8217;s Optimus May Be The First Humanoid Robot To Achieve High Volume And Tech Scale, Says Nvidia CEO Jensen Huang: &#8216;&#8230; Likely To Be The Next Multi-Trillion Dollar Industry&#8217; </a></li>
</ul>
Image: Shutterstock

Analyst Color

Large Cap

Analyst Ratings

Tech

NVDA

Bank Of America Hikes Nvidia Price Target To $180, Sees Annual Earnings Per Share To Hit $10

Editor&#8217;s note: This story has been updated to include a statement from a Tempus AI spokesperson.
Spruce Point Capital Management has announced a new short position against Tempus AI Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>). On Wednesday, the short seller raised concerns about <a href="https://www.benzinga.com/quote/TEM/earnings">the company&#8217;s management team</a>.
What To Know: Tempus AI shares are tumbling Wednesday morning. Shortseller Spruce Point targeted the Chicago-based company in a new report titled &#8220;The Tempest Surrounding Tempus AI.&#8221;
The firm blasted Tempus AI founder and CEO Eric Lefkofsky&#8216;s past. Lefkofsky and his partner Brad Keywell, Spruce says, have a history of promoting disruptive technology companies only to cash out. As a result, shareholders are left behind.
&#8220;We believe that Tempus Labs (now promoted as Tempus AI) is their next big technology promotion that is likely to disappoint,&#8221; the short seller said. 
A spokesperson for Tempus AI told Benzinga that the report is filled with inaccurate information.
&#8220;Some investment firms focus on shorting stocks and publishing content they think will scare off investors. We do not intend to respond to a report that is riddled with hypotheticals and inaccuracies and fails to address Tempus&#8217; history of strong financial performance and impressive growth. We remain focused on delivering shareholder value, taking advantage of the enormous opportunity of bringing AI to healthcare, and helping patients live longer and healthier lives,&#8221; a Tempus spokesperson said.
Spruce Point highlighted the sale of Starbelly.com to HA-LO industries during the dotcom bubble. HA-LO went on to file for bankruptcy in 2001. A lawsuit reportedly revealed that Lefkofsky told his team to be &#8220;wildly positive&#8221; in its forecasts, among other strong commentary.
Lefkofsky and Keywell were also reportedly involved in promoting Groupon, which restated revenues by close to 50%. Groupon shares are down approximately 94.5% since IPO, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>. The duo also promoted InnerWorkings, which went down a similar path, the short seller said. 
Spruce Point raised concerns about several Tempus AI board members who have connections to previous fraud allegations. The short seller now sees signs of &#8220;aggressive and suspicious&#8221; accounting practices at Tempus, including adjusted EBITDA calculations that benefit from a novel debt forgiveness structure and potential circularity of cash flows between related parties that results in revenue for the company. 
Spruce Point noted that although the company rebranded from Tempus Labs to Tempus AI, the company&#8217;s AI-related revenue remains minimal with less than 2% of total revenue coming from AI applications. 
&#8220;This stark disconnect between the Company's branding and its financial reality raises significant questions about the substance of its AI narrative and whether the rebrand reflects true technological leadership or simply an effort to capitalize on prevailing market enthusiasm,&#8221; the short seller said.
Spruce Point also said it has serious concerns about the integrity of the company&#8217;s product as demonstration videos &#8220;call into question the accuracy of its data collection and AI services.&#8221;
The short seller warned investors that it sees potential downside risk of 50% to 60% in Tempus AI shares following a swift rise in the stock so far this year.
Price Action:&nbsp;<a href="http://benzinga.com/quote/tem" target="_blank" rel="noreferrer noopener">Tempus AI shares</a>&nbsp;were down 16.6% at $54.80 at the time of publication Wednesday. Despite Wednesday&#8217;s decline, the stock is still up approximately 62% year-to-date, according to&nbsp;<a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/insights/short-sellers/25/05/45645040/is-the-market-bullish-or-bearish-on-annaly-capital-management">Is the Market Bullish or Bearish on Annaly Capital Management?</a></li>
<li><a href="https://www.benzinga.com/media/25/05/45637684/after-the-delay-nvidias-blackwell-ai-servers-are-back-in-production-as-suppliers-foxconn-inventec-dell-and-wistron-fix-key-technical-issues-report">Nvidia&#8217;s Blackwell AI Servers Are Back In Production After Key Supply Chain Partners Like Foxconn Fix Overheating Issues: Report</a></li>
</ul>
Photo: Piotr Swat/Shutterstock.

Short Sellers

Short Ideas

Trading Ideas

Tempus Fugit, Investors Regret? Short Seller Targets AI Darling, Warns CEO Is 'Cash Out King' (UPDATED)

Analysts' ratings for Ocular Therapeutix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCUL#NASDAQ">OCUL</a>) over the last quarter vary from bullish to bearish, as provided by 7 analysts.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Ocular Therapeutix, revealing an average target of $15.71, a high estimate of $19.00, and a low estimate of $14.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 4.21%. 
<img src="https://www.benzinga.com/files/images/story/2025/1748545320_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Ocular Therapeutix. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yi Chen</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$15.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Serge Belanger</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$14.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Serge Belanger</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$15.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Announces</td>
<td>Outperform</td>
<td>$17.00</td>
<td>-</td>
</tr>
<tr>
<td>Serge Belanger</td>
<td>Needham</td>
<td>Announces</td>
<td>Buy</td>
<td>$15.00</td>
<td>-</td>
</tr>
<tr>
<td>Jonathan Wolleben</td>
<td>Citizens Capital Markets</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$19.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Yi Chen</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$15.00</td>
<td>$15.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Ocular Therapeutix. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Ocular Therapeutix compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Ocular Therapeutix's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Ocular Therapeutix's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/OCUL/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Ocular Therapeutix analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>About Ocular Therapeutix</h2>
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
<h3>A Deep Dive into Ocular Therapeutix's Financials</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Negative Revenue Trend: Examining Ocular Therapeutix's financials over 3M reveals challenges. As of 31 March, 2025, the company experienced a decline of approximately -27.59% in revenue growth, reflecting a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -598.74%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Ocular Therapeutix's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -22.04%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Ocular Therapeutix's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -14.83%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.29, Ocular Therapeutix adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>How Are Analyst Ratings Determined?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

OCUL

Demystifying Ocular Therapeutix: Insights From 7 Analyst Reviews

During the last three months, 5 analysts shared their evaluations of Equity Lifestyle Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELS#NYSE">ELS</a>), revealing diverse outlooks from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $75.2, a high estimate of $80.00, and a low estimate of $70.00. This current average reflects an increase of 0.27% from the previous average price target of $75.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1748545297_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The standing of Equity Lifestyle Props among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anthony Powell</td>
<td>Barclays</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$70.00</td>
<td>-</td>
</tr>
<tr>
<td>Anthony Hau</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$71.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Juan Sanabria</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$77.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Peter Abramowitz</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Buy</td>
<td>$80.00</td>
<td>-</td>
</tr>
<tr>
<td>Juan Sanabria</td>
<td>BMO Capital</td>
<td>Announces</td>
<td>Outperform</td>
<td>$78.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Equity Lifestyle Props. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Equity Lifestyle Props compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Equity Lifestyle Props's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Equity Lifestyle Props's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ELS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Equity Lifestyle Props analyst ratings.</a>
<h2>Delving into Equity Lifestyle Props's Background</h2>
Equity Lifestyle Properties is a residential REIT that focuses on owning manufactured housing, residential vehicle communities, and marinas. The company currently has a portfolio of 452 properties across the U.S. with a higher concentration in the Sunbelt region with 38% of the company's properties located in Florida, 12% in Arizona, and 8% in California. Equity Lifestyle targets owning properties in attractive retirement destinations with over 70% of the company's properties either being age-restricted or having an average resident age over 55.
<h3>Equity Lifestyle Props's Financial Performance</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: Equity Lifestyle Props's remarkable performance in 3M is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of 0.19%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Real Estate sector.
Net Margin: Equity Lifestyle Props's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 29.71%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Equity Lifestyle Props's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 6.26% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Equity Lifestyle Props's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.93% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: With a high debt-to-equity ratio of 1.81, Equity Lifestyle Props faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>Analyst Ratings: What Are They?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What 5 Analyst Ratings Have To Say About Equity Lifestyle Props

10 analysts have expressed a variety of opinions on Skyward Specialty (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKWD#NASDAQ">SKWD</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">8</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $64.3, along with a high estimate of $72.00 and a low estimate of $57.00. This upward trend is apparent, with the current average reflecting a 6.81% increase from the previous average price target of $60.20.
<img src="https://www.benzinga.com/files/images/story/2025/1748545283_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
A comprehensive examination of how financial experts perceive Skyward Specialty is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Meyer Shields</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$72.00</td>
<td>$67.00</td>
</tr>
<tr>
<td>Meyer Shields</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$67.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>Paul Newsome</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$66.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>Mark Hughes</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$70.00</td>
<td>$61.00</td>
</tr>
<tr>
<td>Matthew Carletti</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$65.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Alex Scott</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$64.00</td>
<td>$63.00</td>
</tr>
<tr>
<td>Andrew Andersen</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$59.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Meyer Shields</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$57.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Alex Scott</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$63.00</td>
<td>$53.00</td>
</tr>
<tr>
<td>Reni Benjamin</td>
<td>Citizens Capital Markets</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$60.00</td>
<td>$60.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Skyward Specialty. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Skyward Specialty compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Skyward Specialty's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
For valuable insights into Skyward Specialty's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/SKWD/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Skyward Specialty analyst ratings.</a>
<h2>Get to Know Skyward Specialty Better</h2>
Skyward Specialty Insurance Group Inc is a specialty insurance company that delivers commercial property and casualty products and solutions on a non-admitted and admitted basis. The firm has one reportable segment through which it offers a broad array of insurance coverages to several market niches. It operates multiple lines of business, including general liability, excess liability, professional liability, commercial auto, group accident, health, property, surety, and workers' compensation.
<h3>Skyward Specialty: Delving into Financials</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Skyward Specialty's revenue growth over a period of 3M has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately 25.26%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Financials sector.
Net Margin: Skyward Specialty's net margin excels beyond industry benchmarks, reaching 12.72%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Skyward Specialty's ROE excels beyond industry benchmarks, reaching 5.11%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Skyward Specialty's ROA excels beyond industry benchmarks, reaching 1.08%. This signifies efficient management of assets and strong financial health.
Debt Management: Skyward Specialty's debt-to-equity ratio is below the industry average at 0.14, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Significance of Analyst Ratings Explained</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SKWD

What Analysts Are Saying About Skyward Specialty Stock

Investors with a lot of money to spend have taken a bearish stance on Cameco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCJ#NYSE">CCJ</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with CCJ, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 17 uncommon options trades for Cameco.
This isn't normal.
The overall sentiment of these big-money traders is split between 29% bullish and 47%, bearish.
Out of all of the special options we uncovered, 4 are puts, for a total amount of $358,005, and 13 are calls, for a total amount of $999,957.
<h3>What's The Price Target?</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $20.0 and $70.0 for Cameco, spanning the last three months.
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Cameco's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Cameco's whale activity within a strike price range from $20.0 to $70.0 in the last 30 days. 
<h3>Cameco Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748545275_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CCJ</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$6.35</td>
<td>$6.15</td>
<td>$6.2</td>
<td>$60.00</td>
<td>$365.1K</td>
<td>12.8K</td>
<td align="right">2</td>
</tr>
<tr>
<td>CCJ</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/20/26</td>
<td>$4.4</td>
<td>$4.35</td>
<td>$4.4</td>
<td>$50.00</td>
<td>$119.6K</td>
<td>453</td>
<td align="right">289</td>
</tr>
<tr>
<td>CCJ</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$11.3</td>
<td>$11.3</td>
<td>$11.3</td>
<td>$70.00</td>
<td>$113.0K</td>
<td>478</td>
<td align="right">0</td>
</tr>
<tr>
<td>CCJ</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$3.35</td>
<td>$3.25</td>
<td>$3.25</td>
<td>$55.00</td>
<td>$83.5K</td>
<td>1.2K</td>
<td align="right">282</td>
</tr>
<tr>
<td>CCJ</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$40.8</td>
<td>$40.15</td>
<td>$40.45</td>
<td>$20.00</td>
<td>$80.9K</td>
<td>122</td>
<td align="right">20</td>
</tr>
</tbody>
</table>

<h3>About Cameco</h3>
Cameco Corp is a provider of uranium needed to generate clean, reliable baseload electricity around the globe. one of those uranium producers. It has three reportable segments, Uranium, Fuel Services, and Westinghouse. It derives maximum revenue from the Westinghouse Segment. It has some projects namely; Millennium, Yeelirrie, Kintyre, and Exploration. The company operates in Canada, Kazakhstan, Germany, Australia, and the United States.
After a thorough review of the options trading surrounding Cameco, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Cameco's Current Market Status</h3>
<ul>
<li>Trading volume stands at 4,907,332, with CCJ's price down by -2.33%, positioned at $59.0.</li>
<li>RSI indicators show the stock to be may be overbought.</li>
<li>Earnings announcement expected in 62 days.</li>
</ul>
<h3>Professional Analyst Ratings for Cameco</h3>
Over the past month, 1 industry analysts have shared their insights on this stock, proposing an average target price of $65.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Goldman Sachs has revised its rating downward to Buy, adjusting the price target to $65. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Cameco, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

Options

This Is What Whales Are Betting On Cameco

High-rolling investors have positioned themselves bearish on Archer Aviation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NYSE">ACHR</a>), and it's important for retail traders to take note. 
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in ACHR often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 11 options trades for Archer Aviation. This is not a typical pattern.
The sentiment among these major traders is split, with 18% bullish and 81% bearish. Among all the options we identified, there was one put, amounting to $162,000, and 10 calls, totaling $1,343,656.
<h3>Predicted Price Range</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $11.0 to $15.0 for Archer Aviation during the past quarter. 
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Archer Aviation's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Archer Aviation's whale trades within a strike price range from $11.0 to $15.0 in the last 30 days. 
<h3>Archer Aviation Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748545270_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACHR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/17/25</td>
<td>$2.2</td>
<td>$2.15</td>
<td>$2.15</td>
<td>$11.00</td>
<td>$326.0K</td>
<td>9.6K</td>
<td>6.2K</td>
</tr>
<tr>
<td>ACHR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/17/25</td>
<td>$2.2</td>
<td>$2.15</td>
<td>$2.15</td>
<td>$11.00</td>
<td>$199.9K</td>
<td>9.6K</td>
<td>3.9K</td>
</tr>
<tr>
<td>ACHR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/17/25</td>
<td>$2.17</td>
<td>$2.15</td>
<td>$2.15</td>
<td>$11.00</td>
<td>$190.7K</td>
<td>9.6K</td>
<td>2.6K</td>
</tr>
<tr>
<td>ACHR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/17/25</td>
<td>$2.2</td>
<td>$2.15</td>
<td>$2.15</td>
<td>$11.00</td>
<td>$181.8K</td>
<td>9.6K</td>
<td>1.6K</td>
</tr>
<tr>
<td>ACHR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/17/25</td>
<td>$2.2</td>
<td>$2.15</td>
<td>$2.15</td>
<td>$11.00</td>
<td>$179.3K</td>
<td>9.6K</td>
<td>4.7K</td>
</tr>
</tbody>
</table>

<h3>About Archer Aviation</h3>
Archer Aviation Inc advances the benefits of sustainable air mobility. The company is engaged in designing and developing a fully electric vertical takeoff and landing eVTOL aircraft for use in UAM networks. It is creating an electric airline that moves people throughout cities in a quick, safe, sustainable, and cost-effective manner.
Following our analysis of the options activities associated with Archer Aviation, we pivot to a closer look at the company's own performance.
<h3>Present Market Standing of Archer Aviation</h3>
<ul>
<li>With a volume of 18,846,047, the price of ACHR is down -2.88% at $10.63. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 70 days.</li>
</ul>
<h3>Expert Opinions on Archer Aviation</h3>
A total of 3 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $12.83.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from HC Wainwright &amp; Co. has revised its rating downward to Buy, adjusting the price target to $12. 
&#x2A; In a cautious move, an analyst from Cantor Fitzgerald downgraded its rating to Overweight, setting a price target of $13. 
&#x2A; An analyst from Needham downgraded its action to Buy with a price target of $13. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Archer Aviation, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

ACHR

Decoding Archer Aviation's Options Activity: What's the Big Picture?

Whales with a lot of money to spend have taken a noticeably bullish stance on Etsy.
Looking at options history for Etsy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETSY#NASDAQ">ETSY</a>) we detected 16 trades.
If we consider the specifics of each trade, it is accurate to state that 75% of the investors opened trades with bullish expectations and 12% with bearish.
From the overall spotted trades, 2 are puts, for a total amount of $80,790 and 14, calls, for a total amount of $3,212,253.
<h3>Projected Price Targets</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $22.5 to $75.0 for Etsy during the past quarter. 
<h3>Volume &amp; Open Interest Development</h3>
In today's trading context, the average open interest for options of Etsy stands at 3594.91, with a total volume reaching 76,933.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Etsy, situated within the strike price corridor from $22.5 to $75.0, throughout the last 30 days.
<h3>Etsy Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748545265_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ETSY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$17.25</td>
<td>$15.7</td>
<td>$16.7</td>
<td>$40.00</td>
<td>$1.4M</td>
<td>1.7K</td>
<td align="right">989</td>
</tr>
<tr>
<td>ETSY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$13.65</td>
<td>$13.3</td>
<td>$13.53</td>
<td>$45.00</td>
<td>$1.1M</td>
<td>971</td>
<td align="right">850</td>
</tr>
<tr>
<td>ETSY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$2.12</td>
<td>$2.09</td>
<td>$2.09</td>
<td>$65.00</td>
<td>$104.5K</td>
<td>966</td>
<td align="right">501</td>
</tr>
<tr>
<td>ETSY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$5.0</td>
<td>$4.85</td>
<td>$5.0</td>
<td>$50.00</td>
<td>$95.5K</td>
<td>11.1K</td>
<td align="right">234</td>
</tr>
<tr>
<td>ETSY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$2.29</td>
<td>$2.0</td>
<td>$2.1</td>
<td>$75.00</td>
<td>$75.6K</td>
<td>1.5K</td>
<td align="right">360</td>
</tr>
</tbody>
</table>

<h3>About Etsy</h3>
Etsy operates a top-10 e-commerce marketplace in the US and the UK, with sizable operations in Germany, France, Australia, and Canada. The firm dominates an interesting niche, connecting buyers and sellers through its online market to exchange vintage and craft goods. With $12.5 billion in 2024 consolidated gross merchandise volume, Etsy has cemented itself as one of the largest players in a quickly growing space, generating revenue from listing fees, commissions on sold items, advertising services, payment processing, and shipping labels. As of the end of 2024, the firm connected more than 95 million buyers and 8 million sellers on its marketplace properties: Etsy, Reverb (musical equipment), and Depop (clothing resale).
After a thorough review of the options trading surrounding Etsy, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Where Is Etsy Standing Right Now?</h3>
<ul>
<li>With a trading volume of 5,571,406, the price of ETSY is up by 2.2%, reaching $52.58.</li>
<li>Current RSI values indicate that the stock is may be overbought.</li>
<li>Next earnings report is scheduled for 62 days from now.</li>
</ul>
<h3>Professional Analyst Ratings for Etsy</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $42.2.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from B. Riley Securities persists with their Buy rating on Etsy, maintaining a target price of $55. 
&#x2A; An analyst from Morgan Stanley persists with their Underweight rating on Etsy, maintaining a target price of $38. 
&#x2A; An analyst from Wells Fargo persists with their Underweight rating on Etsy, maintaining a target price of $40. 
&#x2A; An analyst from Goldman Sachs has decided to maintain their Sell rating on Etsy, which currently sits at a price target of $31. 
&#x2A; An analyst from Cantor Fitzgerald has decided to maintain their Neutral rating on Etsy, which currently sits at a price target of $47. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Etsy, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

ETSY

Etsy's Options Frenzy: What You Need to Know

9 analysts have shared their evaluations of Air Products (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APD#NYSE">APD</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $327.33, a high estimate of $370.00, and a low estimate of $282.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 9.33%. 
<img src="https://www.benzinga.com/files/images/story/2025/1748545252_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
A clear picture of Air Products's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vincent Andrews</td>
<td>Morgan Stanley</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$290.00</td>
<td>-</td>
</tr>
<tr>
<td>Joshua Spector</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$324.00</td>
<td>$335.00</td>
</tr>
<tr>
<td>Duffy Fischer</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$325.00</td>
<td>$355.00</td>
</tr>
<tr>
<td>Steve Byrne</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$282.00</td>
<td>$330.00</td>
</tr>
<tr>
<td>Joshua Spector</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$335.00</td>
<td>$370.00</td>
</tr>
<tr>
<td>Michael Sison</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$320.00</td>
<td>$365.00</td>
</tr>
<tr>
<td>Duffy Fischer</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$355.00</td>
<td>$365.00</td>
</tr>
<tr>
<td>Patrick Cunningham</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$345.00</td>
<td>$373.00</td>
</tr>
<tr>
<td>Joshua Spector</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$370.00</td>
<td>$395.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Air Products. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Air Products compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Air Products's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Air Products's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/APD/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Air Products analyst ratings.</a>
<h2>Unveiling the Story Behind Air Products</h2>
Since its founding in 1940, Air Products has become one of the leading industrial gas suppliers globally, with operations in 50 countries and 19,000 employees. The company is the largest supplier of hydrogen and helium in the world. It has a unique portfolio serving customers in a number of industries, including chemicals, energy, healthcare, metals, and electronics. Air Products generated $12.1 billion in revenue in fiscal 2024.
<h3>Financial Milestones: Air Products's Journey</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Challenges: Air Products's revenue growth over 3M faced difficulties. As of 31 March, 2025, the company experienced a decline of approximately -0.48%. This indicates a decrease in top-line earnings. When compared to others in the Materials sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Air Products's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -59.34%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -11.02%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Air Products's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -4.39%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Air Products's debt-to-equity ratio surpasses industry norms, standing at 1.12. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>How Are Analyst Ratings Determined?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Outlook: Air Products Through The Eyes Of 9 Analysts

In the preceding three months, 15 analysts have released ratings for Roblox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBLX#NYSE">RBLX</a>), presenting a wide array of perspectives from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">7</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $77.6, a high estimate of $100.00, and a low estimate of $62.00. Witnessing a positive shift, the current average has risen by 7.18% from the previous average price target of $72.40.
<img src="https://www.benzinga.com/files/images/story/2025/1748545242_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The standing of Roblox among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jason Bazinet</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$100.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Eric Sheridan</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$80.00</td>
<td>$63.00</td>
</tr>
<tr>
<td>Aaron Lee</td>
<td>Macquarie</td>
<td>Raises</td>
<td>Outperform</td>
<td>$80.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Martin Yang</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$80.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Jason Bazinet</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$85.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Ross Sandler</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$62.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Ken Gawrelski</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$78.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Eric Handler</td>
<td>Roth MKM</td>
<td>Raises</td>
<td>Neutral</td>
<td>$74.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Jason Tilchen</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$84.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Mike Hickey</td>
<td>Benchmark</td>
<td>Raises</td>
<td>Buy</td>
<td>$77.00</td>
<td>$71.00</td>
</tr>
<tr>
<td>Michael Pachter</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$83.00</td>
<td>$83.00</td>
</tr>
<tr>
<td>Matthew Cost</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$70.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Martin Yang</td>
<td>Oppenheimer</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$70.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Ken Gawrelski</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$70.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Mike Hickey</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$71.00</td>
<td>$71.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Roblox. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Roblox compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Roblox's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
For valuable insights into Roblox's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/RBLX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Roblox analyst ratings.</a>
<h2>Unveiling the Story Behind Roblox</h2>
Roblox operates a free-to-play online video game platform with about 85 million daily active users. This platform has spawned a virtual universe and a Roblox economy based on the Robux currency. The platform houses millions of games from a wide range of creators spanning from young gamers themselves to professional development studios. Roblox offers creators the tools, publishing abilities, and platform for their games, enabling anyone to create a game. Creators earn money when gamers make optional in-game purchases within their games and by offering space for real-world advertising, and Roblox earns revenue primarily by taking a cut of these earnings.
<h3>A Deep Dive into Roblox's Financials</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: Roblox displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 29.19%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Communication Services sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Roblox's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -20.77%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Roblox's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -80.83%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Roblox's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -2.94%, the company may face hurdles in achieving optimal financial returns.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 5.81, caution is advised due to increased financial risk.
<h2>How Are Analyst Ratings Determined?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

RBLX

Breaking Down Roblox: 15 Analysts Share Their Views

AstraZeneca's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NYSE">AZN</a>) short percent of float has risen 50.0% since its last report. The company recently reported that it has 7.34 million shares sold short, which is 0.24% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.36 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>AstraZeneca Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748545232_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for AstraZeneca has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing AstraZeneca's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, AstraZeneca's peer group average for short interest as a percentage of float is 4.04%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into AstraZeneca's Recent Short Interest

In the current session, the stock is trading at $42.63, after a 0.71% spike. Over the past month, Leonardo DRS Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRS#NASDAQ">DRS</a>) stock increased by 3.82%, and in the past year, by 77.35%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2025/1748545232_0_0.png" alt="Past Year Chart" />

<h3>Evaluating Leonardo DRS P/E in Comparison to Its Peers</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Leonardo DRS has a lower P/E than the aggregate P/E of 72.52 of the Aerospace &amp; Defense industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1748545232_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Price Over Earnings Overview: Leonardo DRS

EyePoint Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYPT#NASDAQ">EYPT</a>) underwent analysis by 5 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $26.0, a high estimate of $33.00, and a low estimate of $22.00. This current average represents a 7.14% decrease from the previous average price target of $28.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1748545228_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive EyePoint Pharmaceuticals. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yi Chen</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$26.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Daniil Gataulin</td>
<td>Chardan Capital</td>
<td>Lowers</td>
<td>Buy</td>
<td>$27.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Daniil Gataulin</td>
<td>Chardan Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$33.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Yi Chen</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.00</td>
<td>$22.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to EyePoint Pharmaceuticals. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of EyePoint Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for EyePoint Pharmaceuticals's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Capture valuable insights into EyePoint Pharmaceuticals's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/EYPT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on EyePoint Pharmaceuticals analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>About EyePoint Pharmaceuticals</h2>
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.
<h3>EyePoint Pharmaceuticals: A Financial Overview</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3M period, EyePoint Pharmaceuticals showcased positive performance, achieving a revenue growth rate of 109.29% as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: EyePoint Pharmaceuticals's net margin excels beyond industry benchmarks, reaching -184.82%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): EyePoint Pharmaceuticals's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -14.24%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): EyePoint Pharmaceuticals's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -11.57%, the company may face hurdles in achieving optimal financial returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.08.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

EYPT

Analyst Expectations For EyePoint Pharmaceuticals's Future

Frontline's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FRO#NYSE">FRO</a>) short percent of float has risen 10.78% since its last report. The company recently reported that it has 8.38 million shares sold short, which is 5.86% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.99 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Frontline Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748545226_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Frontline has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Frontline's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Frontline's peer group average for short interest as a percentage of float is 3.46%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

How Do Investors Really Feel About Frontline?

Bio-Techne's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TECH#NYSE">TECH</a>) short percent of float has risen 12.34% since its last report. The company recently reported that it has 7.20 million shares sold short, which is 5.28% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.66 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Bio-Techne Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748545220_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Bio-Techne has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Bio-Techne's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Bio-Techne's peer group average for short interest as a percentage of float is 7.36%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

TECH

What Does the Market Think About Bio-Techne?

Watching Ford; Reuters Reports Ford Executive Chair Reportedly Says If Ev Production Tax Credits Go Away, Our Michigan Battery Plant Is "Imperiled"

Press Releases

TMCI Investors Have Opportunity to Lead Treace Medical Concepts, Inc. Securities Fraud Lawsuit

Legal

ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Treace Medical Concepts, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – TMCI

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Treace Medical Concepts, Inc of Class Action Lawsuit and Upcoming Deadlines - TMCI

Grabar Law Office Investigates Claims on Behalf of Shareholders of DoubleVerify Holdings, Inc. (NYSE: DV); NAPCO Securities Technologies, Inc. (NASDAQ: NSSC); Pacira Biosciences, Inc. (NASDAQ: PCRX); and Treace Medical Concepts, Inc. (NASDAQ: TMCI)

TREACE MEDICAL CONCEPTS, INC. (NASDAQ: TMCI) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Treace Medical Concepts, Inc. Investors of Upcoming Deadline

Deadline Alert: Treace Medical Concepts, Inc. (TMCI) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit

Small Cap

Treace Medical Concepts, Inc. (TMCI) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

TMCI DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Treace Medical Concepts, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 10 Deadline in Securities Class Action – TMCI

Comments

Treace Medical Concepts

Treace Medical Concepts (TMCI) オプション

Treace Medical Concepts (NASDAQ:TMCI) 株価情報, オプションチェーン

ニュース

パートナーシップ

ベンジンガ・グローバル